NCT04675450
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be candidates for initial therapy with nab-paclitaxel (Abraxane)
Exclusions: 
https://ClinicalTrials.gov/show/NCT04675450